World News: 13:00 GMT Tuesday 3rd December 2019. [DNARx, Inc. via Globe Newswire via SPi World News]
SAN FRANCISCO, Dec. 03, 2019 (GLOBE NEWSWIRE) -- DNARx, LLC announced today the publication in of data demonstrating the capabilities and efficacy of its pioneering HEDGES™ (igh-level xtended uration ene xpression ystem) DNA-based, non-viral gene therapy delivery and expression platformThe article appeared on the website on Wednesday, November 27, 2019. The data in the article demonstrate significant advantages of HEDGES over viral vector-based approaches to gene therapy.
The published results demonstrate that a single HEDGES administration durably produced FDA-approved protein therapies, including cytokines and monoclonal antibodies at therapeutic levels in mice. These results included:
“The article in shows HEDGES’ safety and efficacy as well as HEDGES’ important advantages over viral vector-based gene therapy, such as adeno-associated virus,” said Robert Debs, M.D., CEO of DNARx. These advantages include:
The potential of HEDGES to prevent and treat infectious disease was recognized by the Defense Advanced Research Projects Agency (DARPA), which earlier this year awarded DNARx a research contract focused on developing a universal preventative and treatment strategy for influenza viral infection.
The completion of the seminal mouse studies described in sets the stage for early trials targeting sustained therapeutic protein production in humans.
Daniel Dornbusch, DNARx (415) 497-9933
Globe Newswire: 13:00 GMT Tuesday 3rd December 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.